Amicus Therapeutics, Inc. (NASDAQ:FOLD) registered a -4.26% decrease, still its new closing price is 17.23% up from the company’s 1 year high of 9.83.It posted -3.18% losses in previous 5 sessions and is now the subject of 1 analysts who together assign a hold rating on stock. 0 of Wall Street analysts have an underperform rating; the 0 sells versus 4 buy or better ratings. The 8 stock analysts following this company have an average price target at $11.06, with individual PT in the $8.00-$15.00 range. The shares moved at $5.17, implying that brokerage firms see shares losing about -14.40% in twelve months time.

Amicus Therapeutics, Inc. (FOLD) SEC Form 4 News

The stock is getting much attention these days as insiders are offloading shares while they posted a 4.02% rise year to date. A Chief Science Officer at Amicus Therapeutics, Inc. (FOLD) offloaded shares in a transaction closed on Friday January 13, 2017. Do Hung sold 25,000 shares in the company at $6 each and collected $150,000 in proceeds. Do Hung now owns 559,266 shares in the company after this transaction. A 10% Owner in the company, PERCEPTIVE ADVISORS LLC, disclosed a transaction on Friday December 30, 2016 that ended up paying $469,001 from the purchase of 94,750 shares at $4.96 per share.

Amicus Therapeutics, Inc. (NASDAQ:FOLD) Upcoming Results on Tap

Amicus Therapeutics, Inc. will next provide financial results for the March 2017 quarter. Stock analysts expect it to report per-share earnings of $-0.30 in that period. Sales during the quarter are predicted to arrive at $6.47 million.

Earnings surprise history: Last quarter, the company posted approximately $2.13 million in revenue and EPS of $-0.33. The mean forecast was for $1.71 million and $-0.31 a share, respectively. One quarter earlier, revenue for the stock was at $0, with earnings at $-0.40/share.

Amicus Therapeutics, Inc. (FOLD) Brokerage Update

Amicus Therapeutics, Inc. (FOLD) is in Robert W. Baird’s research list so their analyst rating change is noteworthy. These shares were upgraded to Outperform from Neutral by Robert W. Baird, according to news reported on Tuesday January 24, 2017.Another important research note was issued by Chardan Capital Markets on Wednesday September 16, 2015.The firm downgraded FOLD to Neutral from Buy. Over the last six months and over the last three months, the shares of Amicus Therapeutics, Inc. (FOLD), have changed -23.07% and -30.88%, respectively.